Patent ID: 7666888

Claim:
A compound according to formula I, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: wherein A-B represents O—N, or N(H)—N; each represents a single or double bond such that only two double bonds are simultaneously present in the ring containing A and B; R 1 is selected from the group consisting of H, C 1-8 -alkyl, OC 1-8 -alkyl, C 1-3 -haloalkyl, OH, CN, NO 2 , F, Cl, Br, and I; R 2 is selected from the group consisting of H, aryl, heteroaryl, C 1-8 -alkyl, and C 1-6 -haloalkyl; ring Q, together with the nitrogen atom it contains, is a cyclic moiety according to formula IIa or IIb: wherein R 3 , R 4 , and R 5 are independently selected from the group consisting of H, aryl, heteroaryl, C 1-8 -alkyl, C 1-8 -alkyl-aryl, C 1-8 -alkyl-heteroaryl, C 1-8 -alkyl-C 1-8 -alkoxy, C 3 -C 10 -cycloalkyl, C 3 -C 10 -heterocycloalkyl, N(R′) 2 , —C(O)N(R′) 2 , —N(R′)C(O)OR′; R 5a is H, OH, CN, or CONH 2 ; R 6 is selected from the group consisting of H, aryl, heteroaryl, heteroaryloxy, —N(R′) 2 , —C(O)N(R′) 2 , OH, CN, C 3 -C 10 -cycloalkyl, —C(O)R′; any two of R 3 , R 4 , R 5 , and R 6 , together with the atoms to which they are attached, optionally can combine to form a fused, and optionally further fused, saturated, partially saturated, or unsaturated polycycle containing from 5 to 20 atoms selected from C, N, O, and S; X and Y are independently selected CR′ 2 ; Z is O or CR′ 2 ; and wherein any cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or fused polycycle is optionally substituted with from one to four members selected from the group consisting of oxo, halogen, —CN, —NO 2 , C 1-8 -alkyl, C 2-8 -alkenyl, C 2-8 -alkynyl, C 1-8 -alkoxy, C 1-8 -haloalkyl, C 2-8 -hydroxyalkyl, aryloxy, heteroaryl, —C(O)R′, —C(O)OR′, —NR′C(O)OR″, —OR′, —SR′, —OC(O)R′, —C(O)N(R′) 2 , —S(O)R″, —SO 2 R″, —SO 2 N(R′) 2 , —N(R′) 2 and —NR′C(O)R′; each occurrence of R′ is independently selected from the group consisting of H, C 1-8 -alkyl, C 2-8 -alkenyl, C 2-8 -alkynyl, C 1-14 -alkoxy, C 1-8 -haloalkyl, C 1-8 -hydroxyalkyl, C 1-8 -hydroxy-diaryl-alkyl, C 3-8 -cycloalkyl, C 3-8 -heterocycloalkyl, heteroaryl, phenyl, C 3-8 -cycloalkyl-C 1-6 -alkyl, C 3-8 -heterocycloalkyl-C 1-6 -alkyl, heteroaryl-C 1-6 -alkyl, and aryl-C 1-6 -alkyl; and each occurrence of R″ is independently an unsubstituted member selected from the group consisting of C 1-8 -alkyl, C 2-8 -alkenyl, C 2-8 -alkynyl, C 1-4 -alkoxy, C 1-8 -haloalkyl, C 1-8 -hydroxyalkyl, C 3-8 -cycloalkyl, C 3-8 -heterocycloalkyl, heteroaryl, aryl, C 3-8 -cycloalkyl-C 1-6 -alkyl, C 3-8 -heterocycloalkyl-C 1 -6 -alkyl, heteroaryl-C 1-6 -alkyl, and aryl-C 1-6 -alkyl; m and n are integers independently selected from 0, 1, 2, and 3; provided that the compound is not: 4-[[3-methyl-5-(2,3,4,5-tetrafluoro-6-hydroxyphenyl)-4-isoxazolyl]carbonyl]-morpholine 1-[(5-phenyl-4-isoxazolyl)carbonyl]-piperidine 4-[(5-phenyl-4-isoxazolyl)carbonyl]-morpholine 4-[[3-(5-chloro-2,4-dihydroxyphenyl)-1H-pyrazol-4-yl]carbonyl]-morpholine 4-[[3-(3,4-dimethoxyphenyl)-1H-pyrazol-4-yl]carbonyl]-morpholine